Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.

@article{Langer2014RandomizedPI,
  title={Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.},
  author={Corey J. Langer and Samantha Novello and Keunchil Park and Maciej J Krzakowski and Daniel D Karp and Tony C. W. Mok and Rebecca J. Benner and Judith R Scranton and Anthony J. Olszanski and Jacek Jassem},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2014},
  volume={32 19},
  pages={
          2059-66
        }
}
PURPOSE Figitumumab (CP-751,871), a fully human immunoglobulin G2 monoclonal antibody, inhibits the insulin-like growth factor 1 receptor (IGF-1R). Our multicenter, randomized, phase III study compared figitumumab plus chemotherapy with chemotherapy alone as first-line treatment in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Patients with stage IIIB/IV or recurrent NSCLC disease with nonadenocarcinoma histology received open-label figitumumab (20 mg/kg… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 62 CITATIONS, ESTIMATED 62% COVERAGE

Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment

  • International journal of molecular sciences
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas

  • International journal of molecular sciences
  • 2018
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

2014
2019

CITATION STATISTICS

  • 3 Highly Influenced Citations

  • Averaged 9 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 13 REFERENCES

PDQ Non-Small Cell Lung Cancer Treatment

National Cancer Institute
  • Bethesda, MD, National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/ treatment/non-small-cell-lung/healthprofessional
  • 2011
VIEW 1 EXCERPT

Wittekind C (eds): International Union Against Cancer (UICC), TNM Classification of Malignant Tumours (ed

LH Sobin
  • 2002
VIEW 1 EXCERPT